Previous 10 | Next 10 |
Merus (NASDAQ:MRUS) launched a underwritten public offering of shares; underwriters granted 30-day option to purchase an additional 15% of the shares. Offer size, terms have not yet been disclosed. Net proceeds to be used for advancing the clinical development of its product candida...
Shares of Merus N.V. (NASDAQ:MRUS) traded at a new 52-week high today of $32.90. This new high was reached on above average trading volume as 1.2 million shares traded hands, while the average 30-day volume is approximately 847,000 shares. Merus NV is a clinical-stage immuno-oncology com...
Merus participated in a Type B meeting with the FDA regarding its zenocutuzumab development program and obtained alignment with FDA on registration approach for a potential tumor agnostic indication Merus presented early clinical data on MCLA-158 at the AACR-NCI-EORTC Virtual In...
Shares of Merus N.V. (NASDAQ:MRUS) traded today at $31.66, eclipsing its 52-week high. So far today approximately 1.2 million shares have been exchanged, as compared to an average 30-day volume of 737,000 shares. In the past 52 weeks, Merus N.V. share prices are bracketed by a low of $11...
While the S&P 500 index eked out a ~0.8% gain over the week, its healthcare constituents slipped ~0.3% to record the fifth consecutive weekly loss. Dragged down by biotech stocks, the sector became the second-worst performer in the index. Among healthcare stocks with more than $...
A day of gains on Wall Street helped investors forget some of their recent worries on Thursday. This applied to much-maligned (and much-sold) China-based tech stocks, as Alibaba (NYSE:BABA) led a rally in the sector. Baidu (NASDAQ:BIDU), DiDi (NYSE:DIDI) and NetEase (NASDAQ:NTES) also posted ...
4 Biotech Stocks To Add To Your October 2021 Watchlist In good times and bad, people and investors alike often turn to the health care industry. In particular, biotech stocks remain viable plays in the stock market today, nonetheless. For starters, investors appear to be breathi...
Gainers: Camber Energy (NYSE:CEI) +97%. Merus (NASDAQ:MRUS) +32%. New Fortress Energy (NASDAQ:NFE) +25%. Paltalk (NASDAQ:PALT) +25%. Grom Social Enterprises (NASDAQ:GROM) +20%. DatChat (NASDAQ:DATS) +20%. Jupiter Wellness (NASDAQ:JUPW) +18%. NextPlay Technologies (NASDAQ:NXTP) +19%. Independe...
Gainers: Merus (NASDAQ:MRUS) +36%, Nutriband (OTCQB:NTRB) +16%, Skylight Health (NASDAQ:SLHG) +16%, Rani Therapeutics (NASDAQ:RANI) +12%, Jupiter Wellness (NASDAQ:JUPW) +12%. Losers: Osmotica Pharmaceuticals (NASDAQ:OSMT) -38%, Prelude Therapeutics (NAS...
Shares of Merus (NASDAQ: MRUS) , a clinical-stage biopharmaceutical company, are soaring today in response to positive clinical trial results. Investors impressed with the company's latest presentation pushed the stock 39% higher as of 10:16 a.m. EDT on Thursday. Today, Merus pr...
News, Short Squeeze, Breakout and More Instantly...
UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 24, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ® ), tod...
2024-07-13 04:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ® ), tod...